Sugi Predict

Sugi Predict / Compounds / SCHEMBL951493

SCHEMBL951493

SCHEMBL951493

CC(C)(C)OC(=O)Nc1ncc(C(=O)O)s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ FFAR2 O15552 1/20 0.45
▸ HCAR2 Q8TDS4 1/20 0.45
▸ CCNE1 P24864 4/20 0.44
▸ CDK2 P24941 4/20 0.44
▸ CCNE2 O96020 2/20 0.44
▸ CCNB2 O95067 1/20 0.44
▸ CDK1 P06493 1/20 0.44
▸ CDK4 P11802 1/20 0.44
▸ CCNB1 P14635 1/20 0.44
▸ CCND1 P24385 1/20 0.44
▸ CCNB3 Q8WWL7 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ LCK P06239 4/20 0.41
▸ CDK5 Q00535 2/20 0.41
▸ PI4KB Q9UBF8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1984391 0.98 CA1 (0.45) CA1CA2FFAR2HCAR2CCNE1
SCHEMBL1131936 0.90 FFAR2 (0.48) CA1CA2FFAR2CCNE1CDK2
SCHEMBL5027792 0.88 CA1 (0.44) CA1CA2CCNE1CDK2CCNE2
SCHEMBL12715493 0.88 CCNE1 (0.50) CA1CA2CCNE1CDK2CCNE2
SCHEMBL1984390 0.87 CA1 (0.45) CA1CA2CCNE1CDK2CCNE2
SCHEMBL949743 0.85 CA1 (0.44) CA1CA2CCNE1CDK2CCNE2
SCHEMBL5023749 0.84 CA1 (0.43) CA1CA2FFAR2CCNE1CDK2
SCHEMBL16753888 0.83 CCNE1 (0.43) CA1CA2CCNE1CDK2CCNE2
SCHEMBL29632538 0.83 KDM4E (0.51) CCNE1CDK2KDM4EALDH1A1HPGD
SCHEMBL31242797 0.82 CCNE1 (0.43) CA1CA2CCNE1CDK2CCNE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4676923-A1 BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS Cancer Research Technology Limited (GB) 2026-01-14 — — EP disclosed
WO-2025215187-A1 THERAPEUTIC COMPOUNDS AND THEIR USE MY-T BIO LIMITED (GB) 2025-10-16 — — WO disclosed
US-12384773-B2 Thiazole compounds and methods of use thereof ARCUS BIOSCIENCES, INC. (US) 2025-08-12 — — US disclosed
WO-2025096979-A1 THIAZOLE COMPOUNDS AS KIT INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2025-05-08 — — WO disclosed
US-20250145606-A1 THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2025-05-08 — — US disclosed
EP-4499630-A1 BCL-XL INHIBITORS BeiGene, Ltd. (KY) 2025-02-05 — — EP disclosed
US-20250034128-A1 BCL-XL INHIBITORS BEIGENE, LTD. (KY) 2025-01-30 — — US disclosed
CN-118994050-A Dasatinib intermediate Synthesis method of intermediate 扬州市普林斯医药科技有限公司 2024-11-22 — — CN disclosed
CN-118974033-A Bcl-xL inhibitors 百济神州有限公司 2024-11-15 — — CN disclosed
CN-113727713-B Use of fluorine substituted 2-aminothiazole-5-aromatic formamide 湖南华纳大药厂股份有限公司 2024-09-24 — — CN disclosed
EP-1709018-A1 ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS Sanofi-Aventis (FR) 2006-10-11 — — EP disclosed
US-6972297-B2 2-Hydroxy-mutilin carbamate derivatives for antibacterial use SMITHKLINE BEECHAM P.L.C. (GB) 2005-12-06 — — US disclosed
WO-2005073202-A1 ACYLAMINOTHIAZOLE DERIVATIVES AND USE THEREOF AS BETA-AMYLOID INHIBITORS SANOFI-AVENTIS (FR) 2005-08-11 — — WO disclosed
EP-1390034-A4 N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2005-07-13 — — EP disclosed
EP-1390034-A1 N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS Merck & Co., Inc. (US) 2004-02-25 — — EP disclosed
US-20030119811-A1 N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists MERCK SHARP & DOHME CORP. 2003-06-26 — — US disclosed
US-20030114674-A1 2-Hydroxy-mutilin carbamate derivatives for antibacterial use SMITHKLINE BEECHAM P.L.C. (GB) 2003-06-19 — — US disclosed
EP-1268443-A1 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE SmithKline Beecham p.l.c. (GB) 2003-01-02 — — EP disclosed
WO-2002080928-A1 N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2002-10-17 — — WO disclosed
WO-2001074788-A1 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE SMITHKLINE BEECHAM PLC (GB) 2001-10-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114674-A1 2-Hydroxy-mutilin carbamate derivatives for antibacterial use MSH6, MSH2, PMS2 CA1 4500/4885CA2 2069/4885FFAR2 2449/4885
US-12384773-B2 Thiazole compounds and methods of use thereof TPMT, CYP11B2, ABAT CA1 3363/4885CA2 1936/4885FFAR2 1832/4885
US-20250034128-A1 BCL-XL INHIBITORS BCL2, BCL2L1, BCL2L10 CA1 3174/4885CA2 3606/4885FFAR2 2872/4885
US-20250145606-A1 THIAZOLE COMPOUNDS AND METHODS OF USE THEREOF TPMT, CYP11B2, ABAT CA1 3363/4885CA2 1936/4885FFAR2 1832/4885
US-20030119811-A1 N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists GRIN1, GRIN2B, GRIN2A CA1 737/4885CA2 1509/4885FFAR2 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.